drugset
drugset / Trial / NCT05689203

A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19

NCT05689203 ↗

Phase 2 Unknown 360 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19

Timeline

Start
2022-12-30
Primary completion
2023-02-01
Completion
2023-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS1128 Unknown — Oral

Indications

COVID-19